Patients suffering from Gastroesophageal Reflux Disease (GERD), benefit greatly from esomeprazole. Also known as Prilosec I.V. in the United States, AstraZeneca will see their patent of this breakout drug expire in May of 2014. The International Foundation for Functional Gastrointestinal Disorders recently reported that health professionals from the American Gastroenterological Association estimate that 33 percent of people in the United States have acid reflux disease. This astounding number highlights the need not only for continued medical treatments, but also for innovative research to help treat this condition. As GERD is considered to be the most expensive chronic gastrointestinal disorder in the United States, an estimated 10 billion dollars in cumulative cost is spent annually.
Esomeprazole is effectual in treating several other conditions, in addition to acid reflux. Patients suffering from Erosive Esophagitis will typically be prescribed four to eight weeks of treatment with esomeprazole, as well as a maintenance dosing protocol, which could last up to six months. Safe for infants between one month and one year of age, esomeprazole is effective for treating erosive esophagitis due to acid-mediated GERD. Adults and children ages one and older with Symptomatic Gastroesophageal Reflux Disease and heartburn benefit from esomprazole for short term treatment, usually no longer then two months. Appropriately used to treat patients with H. pylori, esomeprazole is formidable when the need to eradicate H. pylori is necessary to reduce the risk of duodenal ulcer occurrences. Part of an adjunctive therapy, esomeprazole is combined with amoxicillin and clarithromycin to eliminate both H. pylori and duodenal ulcer risk in susceptible patients. Patients with Zollinger-Ellison Syndrome, a rare disorder characterized by one or more tumors in the duodenum, pancreas or both, often receive treatment with esomeprazole. These tumors cause the stomach to make excess acid, which in turn leads to peptic ulcers in the duodenum. Esomeprazole is approved and indicated for the long-term treatment of this pathological hypersecretory condition, which provides a worthy symptom reduction in stomach acid secretions in patients with this deleterious condition.
In the class of drugs known as proton pump inhibitors, esomeprazole is offered in the following doses in it’s brand name form, Prilosec: 20 and 40 milligram capsules,. 20 and 40 milligrams of intravenous preparation, and a powder for oral suspension of 10, 20, and 40 milligram doses for mixing. Potential adverse effects include nausea, vomiting, diarrhea, dizziness, rash, and muscle pain.
LGM Pharma is a provider of the Esomeprazole CAS# 119141-88-7 API and offers comprehensive client support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.